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Background/Introduction
Custodiol cardioplegia is attractive method of myocar-
dial protection, as a single dose provides a long period
of preservation. Despite widespread use in Europe, the
available data confirming its efficacy is little compared
with conventional methods of cardioplegia. Custodiol
solution is administered in a single-dose, allowing the
operation to be done continuously. This is an advantage
over other cardioplegic solutions that may have to be re
administered every 20-30 minutes.
Aims/Objectives
Is to compare the efficacy of Custodiol to standard
Plegisol blood cardioplegia in adult cardiac surgical cases.
Method
This study was a single-center retrospective review of
prospectively collected data. Adult cardiac surgery cases
performed between January 2011 and August 2013
using Custodiol® were compared to cases using standard
Plegisol blood cardioplegia. The endpoints of intra-
operative and post-operative were compared including
30-day mortality, hospital readmission, prolonged
mechanical ventilation time, and renal failure.
Results
Of the 100 cases identified, 40 cases used Custodiol and
60 used blood Cardioplegia. Demographics data were
similar in both groups with a mean patient age of 60 ±
14.1 years for Custodiol and 66 ± 10 years for blood car-
dioplegia. The average cardiopulmonary bypass time for
Custodiol and blood cardioplegia was 122 ± 60 and 135 ±
54 minutes respectively. The Custodiol group had a
greater incidence of prolonged ventilation (>24 hours),
20% versus 15 % respectively, and this approached statis-
tical significance with a p value of (0.05). Intra-operative
blood usage was significantly higher in the Custodiol
group compared to the blood cardioplegia group, with
44% of patients receiving fresh frozen plasma during the
operation compared to only 25% in the blood cardiople-
gia group (p = 0.005). There is no statistically significant
difference in 30-day mortality, hospital readmission, and
renal failure.
Discussion/Conclusion
Custodiol is effective for myocardial protection with dis-
tinct advantage of long-term ischemic tolerance although
the use of custodiol increase the need of fresh frozen
plasma during the perioperative period when compared
to blood cardioplegia.
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